FDA approves AstraZeneca's Lynparza

FDA granted accelerated approval to Lynparza olaparib from AstraZeneca plc (LSE:AZN; NYSE:AZN) as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated advanced ovarian cancer, as detected by an FDA-approved test, who have been treated with three or more prior lines of chemotherapy.

AstraZeneca spokesperson Michelle Meixell told BioCentury the company expects to launch the drug by year end. Meixell would not disclose its price. ...